Basf Aktiengesellschaft

Peter C Thieme

Dieter Lenke

Josef Gries

Albrecht Franke

Fritz-Frieder Frickel

Helmut Hagen

Hans Theobald

Gerd Steiner

Hans-Juergen Teschendorf

Hans P Hofmann

Horst Kreiskott

Hubert Sauter

Wolfgang Rohr

Gernot Reissenweber

Rainer Schlecker

Claus D Mueller

Hans-Jurgen Teschendorf

Hans D Lehmann

Harald Weifenbach

Martin Traut

Peter Schmidt

Sterically pure .beta.-triazolyl carbinols of the general structure ##STR1## where R is not hydrogen, in particular the R*, S*-diastereomer, are obtained by diastereoselective reduction of the corresponding .alpha.-triazolylketone with a complex hydride which reduces ketones to alcohols, in the presence of a Lewis acid in a non-polar solvent.

Diastereoselective reduction of alpha-triazolylketones to

Novel phenylpiperazinylpropane and -butane derivatives of hetarylphenols and hetarylanilines of the formula ##STR1## where R.sup.1 is hydrogen or alkyl of 1 to 4 carbon atoms, R.sup.2 is hydrogen, halogen, alkyl of 1 to 4 carbon atoms or alkoxy where alkyl is of 1 to 3 carbon atoms, the phenyl ring can be monosubstituted or disubstituted by R.sup.2, X is oxygen or an NH group, and the heterocyclic structure Het. is 1,3,4-oxadiazolyl, triazolyl, imidazolyl or pyrazolyl, and their physiologically tolerated addition salts with acids, processes for their preparation, and pharmaceutical formulations which contain these compounds and exhibit predominantly sedative, neuroleptic and hypotensive properties.

Phenylpiperazine derivatives of hetarylphenols and hetarylanilines,

Sulfonates of hydroxycoumarins of the formula I ##STR1## where R.sup.1 and R.sup.2 are identical or different and are each hydrogen, halogen or alkyl of 1 to 5 carbon atoms which can be substituted by --NR.sup.4 R.sup.5, --OR.sup.4 or --OC(O)R.sup.4, where R.sup.4 and R.sup.5 are identical or different and are each hydrogen or alkyl of 1 to 4 carbon atoms, or R.sup.1 and R.sup.2 are each a carboxylic acid group --OC(O)R.sup.4 or a carboxamido radical, with the proviso that R.sup.1 is not methyl when R.sup.2 is hydrogen, or R.sup.1 and R.sup.2 together form a --(CH.sub.2).sub.n -- chain where n is 3-5, and R.sup.3 is a straight-chain or branched alkyl radical of 1 to 8 carbon atoms or cycloalkyl of 3 to 8 carbon atoms, each of which can be substituted by halogen, --OR.sup.4, --NR.sup.4 R.sup.5, --CN or phenyl, or R.sup.3 is a straight-chain or branched alkenyl radical of 3 to 8 carbon atoms, an amino group -- NR.sup.4 R.sup.5, or phenyl or naphthyl, each of which is unsubstituted or monosubstituted or polysubstituted by --OR.sup.4, --NR.sup.4 R.sup.5, --NO.sub.2, halogen, --SR.sup.4, --S(O)R.sup.4, --OS(O)R.sup.4, --SCF.sub.3, --OS(O)CF.sub.3, --CN, --C(O)R.sup.4, --OC(O)R.sup.4, --NHC(O)R.sup.4, --CF.sub.3, C.sub.1 -C.sub.4 -alkyl or a combination of these substituents, a process for their preparation, drugs containing these compounds, and compounds of the formula I, in which R.sup.1 is methyl and R.sup.2 is hydrogen, for use as drugs.

Sulfonates of hydroxycoumarins

Novel (hetarylphenoxy)-(phenylpiperazinyl)-propanols of the formula ##STR1## where R.sup.1 is hydrogen, amino or alkyl of 1 to 4 carbon atoms, R.sup.2 is hydrogen, halogen, alkyl of 1 to 4 carbon atoms or alkoxy where alkyl is of 1 to 3 carbon atoms, the phenyl ring can be monosubstituted or disubstituted by R.sup.2, and the heterocyclic structure Het. is pyrimidinyl, triazol-1-yl, imidazol-1-yl, pyrazol-3-yl or isoxazol-3-yl, and their physiologically tolerated addition salts with acids, processes for their preparation, and pharmaceutical formulations which contain these compounds and exhibit predominantly hypotensive, sedative, neuroleptic and broncholytic properties.

(Hetarylphenoxy)-(phenylpiperazinyl)-propanols, their preparation and

Novel aminopropanol derivatives of 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazole and their addition salts with acids, their preparation, pharmaceutical formulations containing these compounds, and their use as drugs in the treatment of coronary heart disease, hypertonia and cardiac arrhythmias.

Amino derivatives of 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazole,

Novel phenylpiperazinylpropanols of 1,3,4-oxadiazolylphenols and their physiologically tolerated addition salts with acids, processes for their preparation, and pharmaceutical formulations which contain these compounds and are useful in the treatment of hypertonia.

Phenylpiperazine derivatives of 1,3,4-oxadiazolylphenols, and

Novel aminopropanol derivatives of 5-(2-hydroxystyryl)-isoxazole and their addition salts with acids, their preparation, pharmaceutical formulations containing these compounds, and their use in the treatment of hypertonia, coronary heart disease and cardiac arrhythmias.

Novel amino derivatives of 5-(2-hydroxystyryl)-isoxazole, their

Alkylaminopropanol derivatives of 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazole and their addition salts with acids, their preparation, and pharmaceutical formulations, containing these compounds, which may be used for the treatment of coronary diseases of the heart, of hypertonia and of cardiac arrhythmias.

Pharmaceutical agent containing amino derivatives of

2-Methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazole of the formula ##STR1## and processes for its preparation by condensing salicylaldehyde with 2,5-dimethyl-1,3,4-thiadiazole or 2-methyl-5-(triphenylphosphine-methylene)-1,3,4-thiadiazole. 2-Methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazole is a valuable intermediate for the preparation of pharmacologically active compounds; for example the alkylamino-hydroxypropyl ethers can, because of their .beta.-sympatholytic action, be used as drugs for the treatment of coronary diseases of the heart, cardiac arrhythmias and hypertonia.

2-Methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazole

Alkylamino-propanol derivatives of 3-alkyl-5-(2-hydroxystyryl)-isoxazole, of the general formula ##STR1## where R is hydrogen, alkyl of 1 to 8 carbon atoms, which is unsubstituted or substituted by hydroxyl, alkoxy of 1 to 3 carbon atoms or cycloalkyl with 3 to 8 carbon atoms in the ring, alkenyl or alkynyl of 2 to 8 carbon atoms, or cycloalkyl with 3 to 8 carbon atoms in the ring, the cycloalkyl rings being unsubstituted or mono- or di-substituted by alkyl of 1 to 3 carbon atoms, and R' is alkyl of 1 to 4 carbon atoms, and their addition salts with physiologically acceptable acids, their preparation, and pharmaceutical formulations which contain these compounds and which can be used as valuable drugs in the treatment of hypertonia, coronary diseases of the heart and cardiac arrhythmias.

Amino derivatives of 3-alkyl-5-(2-hydroxystyryl)-isoxazoles

Novel alkylaminopropanol derivatives of 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazole and their addition salts with acids, their preparation, and pharmaceutical formulations, containing these compounds, which may be used for the treatment of coronary diseases of the heart, of hypertonia and of cardiac arrhythmias.

Growing community of inventors

Wachenheim, Germany

Peter C Thieme